Singapore whistling as Penthrox arrives
Medical device manufacturer Medical Developments International (ASX:MVP) has received regulatory approval from the Health Sciences Authority in Singapore to market and sell Penthrox. MVP is the only global supplier of Penthrox, an emergency pain relief device developed in Australia and commonly known as “the green whistle”. The approval follows the recent European licence, development and commercialisation agreement that was finalised between MVP and Mundipharma International, with Mundipharma paying MVP upfront and milestone payments of up to $54.5 million US dollars. MVP shares have risen significantly in September, and closed up 9.8% for the week. We own MVP in the investment portfolio.
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Wilson Asset Management has a track record of making a difference for shareholders and the community for 27 years and is the investment manager for nine LICs and two unlisted funds. Wilson Asset Management invests over $6 billion on behalf of more than 130,000 retail investors. Wilson Asset Management created and is the lead supporter of the Future Generation companies, the first LICs to deliver both investment and social returns.
1 topic
1 stock mentioned
Comments
Comments
Sign In or Join Free to comment
most popular
Equities
Wisetech tanks 17% on earnings miss but margins shine
Livewire Markets
Equities
21 ASX stocks that should be on your radar
Livewire Markets